Xeris Biopharma Holdings, Inc. 8-K

What Happened

• On January 8, 2026, Xeris Biopharma Holdings, Inc. announced preliminary financial results for the fourth quarter and full year ended December 31, 2025 in a press release.
• The announcement was made via Form 8-K (Item 2.02) and the press release is attached as Exhibit 99.1 to the filing. The report was signed by Chief Financial Officer Steven M. Pieper.

Key Details

• Date of filing/announcement: January 8, 2026.
• Period covered: Q4 and full year ended December 31, 2025.
• Disclosure type: Preliminary results announced in a press release (Exhibit 99.1); Inline XBRL cover page included (Exhibit 104).
• Form 8-K signed by: Steven M. Pieper, Chief Financial Officer.

Why It Matters

• This 8-K alerts investors that Xeris has reported preliminary quarterly and full-year earnings information — a material update on the company’s recent financial performance.
• Investors should review the attached press release for the specific figures and monitor subsequent filings (e.g., quarterly/annual reports) for audited and detailed financial statements.